<ul><li>Johnson & Johnson MedTech reported positive results from a study of its Monarch platform for robotic bronchoscopy procedures, showing a high success rate in reaching and biopsying lung nodules with a good safety profile.</li><li>The study, TARGET, involved 679 patients across 21 global sites and demonstrated a diagnostic yield of 83.2% with Monarch reaching the lesions in 98.7% of cases.</li><li>Investigators identified factors associated with higher diagnostic yield and recognized robotic-assisted bronchoscopy as a safe and effective option that could elevate the standard of care for patients.</li><li>Johnson & Johnson is committed to advancing innovation in robotic-assisted procedures, with the Monarch system enabling minimally invasive access to hard-to-reach lung nodules, while also working on bringing its OTTAVA Robotic Surgical System to the market.</li></ul>

J&J reports positive Monarch robotic bronchoscopy data

Discover more